Prevention of Fibrosis and Pathological Cardiac Remodeling by Salinomycin

Circ Res. 2021 May 28;128(11):1663-1678. doi: 10.1161/CIRCRESAHA.120.317791. Epub 2021 Apr 7.

Ryan M Burke¹, Ronald A Dirkx Jr¹, Pearl Quijada¹, Janet K Lighthouse¹, Amy Mohan¹, Meghann O'Brien², Wojciech Wojciechowski², Collynn F Woeller^{3

4}, Richard P Phipps^{3

4}, Jeffrey D Alexis⁴, John M Ashton², Eric M Small^{1

4

5

6}

¹ Aab Cardiovascular Research Institute, Department of Medicine (R.M.B., R.A.D., P.Q., J.K.L., A.M., E.M.S.), University of Rochester School of Medicine and Dentistry, NY.
² Genomics Research Center (M.O., W.W., J.M.A.), University of Rochester School of Medicine and Dentistry, NY.
³ Environmental Medicine (C.F.W., R.P.P.), University of Rochester School of Medicine and Dentistry, NY.
⁴ Department of Medicine (C.F.W., R.P.P., J.D.A., E.M.S.), University of Rochester School of Medicine and Dentistry, NY.
⁵ Pharmacology and Physiology (E.M.S.), University of Rochester School of Medicine and Dentistry, NY.
⁶ Biomedical Engineering, University of Rochester, NY (E.M.S.).

Abstract

[Figure: see text].

Keywords: fibroblasts; fibrosis; mice; myocardial infarction; salinomycin.